A bridging dose-escalation study of the safety, pharmacokinetic properties, and immunologic effect of subcutaneous L2-7001 (recombinant human interleukin-2) [aldesleukin] in patients infected with HIV with CD4+ T-cell counts of 300 to 500 cells/mm3 and viral burden under 10,000 copies/ml on active antiretroviral therapy (ART)

Trial Profile

A bridging dose-escalation study of the safety, pharmacokinetic properties, and immunologic effect of subcutaneous L2-7001 (recombinant human interleukin-2) [aldesleukin] in patients infected with HIV with CD4+ T-cell counts of 300 to 500 cells/mm3 and viral burden under 10,000 copies/ml on active antiretroviral therapy (ART)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2005

At a glance

  • Drugs Aldesleukin; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top